Pellepharm, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2012-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.pellepharm.com
Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle Applied Once or Twice Daily to Decrease the GLI1 Biomarker in Sporadic Nodular Basal Cell Carcinomas
- First Posted Date
- 2016-07-11
- Last Posted Date
- 2019-01-08
- Lead Sponsor
- PellePharm, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT02828111
- Locations
- 🇺🇸
12121 Bluff Creek Drive Suite 100, Los Angeles, California, United States
Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients
- First Posted Date
- 2016-05-04
- Last Posted Date
- 2020-07-23
- Lead Sponsor
- PellePharm, Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT02762084
- Locations
- 🇬🇧
Manchester Royal Infirmary, Manchester, United Kingdom
🇬🇧Royal London Hospital, London, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath